Has clofazimine been included in the scope of medical insurance reimbursement?

Clofazimine (Clofazimine) is a drug with antibacterial and immunomodulatory effects. It has long been widely used in combination chemotherapy regimens forleprosy, and is especially suitable for maintenance treatment of patients with multibacillary leprosy (MB type). Domestically, this drug has completed registration approval and been launched on the market. It is currently included in the national medical insurance catalog, which means that patients who meet the indications can enjoy a certain degree of cost reduction according to the national medical insurance policy. Clofazimine is a Class B drug under medical insurance, and its reimbursement ratio varies depending on regional policies. Some of the drugs can be reimbursed only after a doctor issues a medical insurance prescription.

The original research and development of clofazimine originated in the last century and was originally developed by the Swiss company Novartis. Due to its strong fat solubility and high tissue affinity, the drug is widely distributed in the body, especially in the skin, liver and lung tissue for long-term storage, making it advantageous in controlling the course of chronic diseases. Currently, in clinical practice, in addition to leprosy, it is also being used for the adjuvant treatment of non-tuberculous mycobacterial (NTM) infections, lupus erythematosus, and certain other inflammatory diseases. Although these uses have not yet been widely included in the official indications in China, they have been used exploratoryly in some cutting-edge medical institutions.

With the support of medical insurance policies, the medication accessibility of clofazimine has been greatly improved, especially for patients with chronic infectious diseases with heavy financial burdens. Medical insurance coverage reduces the risk of treatment interruption and improves compliance and treatment success rates. However, patients need to pay attention to possible side effects while using clofazimine, including skin pigmentation, gastrointestinal discomfort and rare liver function abnormalities. Therefore, it is recommended to use it under the guidance of a doctor. It is worth noting that due to its accumulation characteristics in the body, the drug can continue to be released for several weeks after stopping the drug. Therefore, the treatment course management should be dynamically adjusted based on the individual condition.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine